RxDoctor Payments Data

Tian Zhao, MD

Pain Medicine · Mesquite, TXNPI 1336374727

Payments from drug & device makers

$7,314in general payments, 2019–2025

Across 441 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Scilex Pharmaceuticals Inc.$824
  • Amgen$754
  • Abbott$672
  • Collegium Pharmaceutical, Inc.$460
  • Medtronic$423
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$541%
  • Food & beverage$7,26099%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,314 in reported general payments places this provider in the 65th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$257,812
Medicare patients
65
Services billed
3,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant25$28,119
Aimovig AutoinjectorErenumab-Aooe37$27,648
UbrelvyUbrogepant19$25,533
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen883$21,034
ZtlidoLidocaine39$15,373
Ajovy SyringeFremanezumab-Vfrm14$11,521
BelbucaBuprenorphine Hcl11$6,796
MovantikNaloxegol Oxalate11$6,366
Lidocaine37$4,095
Buprenorphine18$2,933
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen48$1,874
Gabapentin138$1,786
Tramadol Hcl54$1,601
Cyclobenzaprine Hcl214$1,454
Tizanidine Hcl179$1,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$1,292$53,65344 claims
Scilex Pharmaceuticals Inc.Ztlido$824$15,37339 claims
Collegium Pharmaceutical, Inc.Belbuca$460$6,79611 claims
Redhill Biopharma Inc.Movantik$21$6,36611 claims
Upsher-smith Laboratories LLCTopiramate$17$15324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Mesquite

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →